April 23 (Reuters) - The U.S. Centers for Disease

Control and Prevention (CDC) on Tuesday alerted clinicians about

risks of counterfeit versions of AbbVie's ( ABBV ) Botox that

were given to consumers for cosmetic purposes in multiple

states.

The CDC, U.S. Food and Drug Administration (FDA) and state

and local partners are investigating reports of harmful

reactions among people who received injections of counterfeit

Botox.